In the last trading session, 1.57 million Regenxbio Inc (NASDAQ:RGNX) shares changed hands as the company’s beta touched 1.29. With the company’s per share price at $7.80 changed hands at $0.8 or 11.43% during last session, the market valuation stood at $390.67M. RGNX’s last price was a discount, traded about -196.67% off its 52-week high of $23.14. The share price had its 52-week low at $5.62, which suggests the last value was 27.95% up since then. When we look at Regenxbio Inc’s average trading volume, we note the 10-day average is 0.97 million shares, with the 3-month average coming to 1.16 million.
Analysts gave the Regenxbio Inc (RGNX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.42. If we narrow down to specifics, the data shows that 0 out of 6 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended RGNX as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight. Regenxbio Inc’s EPS for the current quarter is expected to be 0.34.
Regenxbio Inc (NASDAQ:RGNX) trade information
Instantly RGNX was in green as seen at the end of in last trading. With action 27.66%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 0.91%, with the 5-day performance at 27.66% in the green. However, in the 30-day time frame, Regenxbio Inc (NASDAQ:RGNX) is 6.85% up. Looking at the short shares, we see there were 6.28 million shares sold at short interest cover period of 8.44 days.
The consensus price target for the stock as assigned by Wall Street analysts is 22, meaning bulls need an upside of 64.55% from its current market value. According to analyst projections, RGNX’s forecast low is 18 with 30 as the target high. To hit the forecast high, the stock’s price needs a -284.62% plunge from its current level, while the stock would need to soar -130.77% for it to hit the projected low.
Regenxbio Inc (RGNX) estimates and forecasts
Year-over-year growth is forecast to reach 280.72% up from the last financial year.
Consensus estimates given by 9 financial analysts project the company’s revenue in the current quarter to hit an average of 93.78M. 9 analysts are of the opinion that Regenxbio Inc’s revenue for the current quarter will be 36.36M. The company’s revenue for the corresponding quarters a year ago was 15.62M and 22.3M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 500.31%. The estimates for the next quarter sales put growth at 63.07%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -12.18%. The 2025 estimates are for Regenxbio Inc earnings to increase by 90.00%, but the outlook for the next 5-year period is at 28.92% per year.
RGNX Dividends
Regenxbio Inc is expected to release its next quarterly earnings report on 2025-Mar-12.
Regenxbio Inc (NASDAQ:RGNX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 7.31% of Regenxbio Inc shares while 87.49% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 94.39%. There are 87.49% institutions holding the Regenxbio Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 18.8252% of the shares, roughly 8.61 million RGNX shares worth $100.73 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 11.1818% or 5.11 million shares worth $59.83 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were JP Morgan Small Cap Growth Fund and Vanguard Total Stock Market Index Fund . With 1.99 shares estimated at $15.52 million under it, the former controlled 3.97% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 2.80% of the shares, roughly 1.4 shares worth around $10.92 million.
